Improved Dosimetric and Clinical Outcomes with Intensity-Modulated Radiotherapy for Head-and-Neck Cancer of Unknown Primary Origin

Strategic Insights -

Researchers at the University of California conducted a study to compare the effectiveness of intensity-modulated radiotherapy (IMRT) and conventional radiotherapy (CRT) for head-and-neck cancer of unknown primary origin. The study reviewed medical records of 51 patients treated with radiation therapy and found that IMRT resulted in significant improvements in dosimetric analysis and reduced side effects. The researchers concluded that IMRT improves the therapeutic ratio among patients with head-and-neck cancer of unknown primary origin.

Key Takeaways:

  • The study compared the effectiveness of IMRT and CRT for head-and-neck cancer of unknown primary origin, reviewing medical records of 51 patients.
  • 47% of patients were treated with CRT, while 53% were treated with IMRT.
  • The proportions of patients receiving concurrent chemotherapy were 54% for CRT and 63% for IMRT.
  • The 2-year estimates of overall survival, local-regional control, and disease-specific survival for the entire patient population were 86%, 89%, and 84%, respectively.
  • IMRT resulted in significant improvements in mean dose and V30 to the contralateral (spared) parotid gland, as well as reduced mean doses to the ipsilateral inner and middle ear structures.
  • The researchers concluded that IMRT improves the therapeutic ratio among patients with head-and-neck cancer of unknown primary origin.

Statistics:

  • 51 patients were included in the study.
  • 24 patients (47%) were treated with CRT, while 27 (53%) were treated with IMRT.
  • 54% of patients receiving CRT and 63% of patients receiving IMRT also received concurrent chemotherapy.
  • The 2-year estimates of overall survival, local-regional control, and disease-specific survival were 86%, 89%, and 84%, respectively.

Sources:

  • Chen, A. M., et al. "Improved Dosimetric and Clinical Outcomes with Intensity-Modulated Radiotherapy for Head-and-Neck Cancer of Unknown Primary Origin." International Journal of Radiation Oncology Biology Physics, vol. 79, no. 3, 2011, pp. 756-762.